InterMune Inc  

(Public, NASDAQ:ITMN)   Watch this stock  
44.07
+0.20 (0.46%)
Aug 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 42.83 - 44.83
52 week 10.95 - 47.72
Open 43.90
Vol / Avg. 1.70M/1.67M
Mkt cap 4.36B
P/E     -
Div/yield     -
EPS -2.66
Shares 98.88M
Beta 5.04
Inst. own 105%
Aug 13, 2014
InterMune Inc at Canaccord Genuity Growth Conference - 3:00PM EDT - Add to calendar
Aug 6, 2014
Q2 2014 InterMune Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 6, 2014
Q2 2014 InterMune Earnings Release - 4:00PM EDT - Add to calendar
Jun 24, 2014
InterMune Inc at JMP Securities Healthcare Conference
Jun 17, 2014
InterMune Inc at Wells Fargo Healthcare Conference
Jun 2, 2014
InterMune at Jefferies Global Healthcare Conference
May 21, 2014
InterMune at UBS Global Healthcare Conference
May 20, 2014
InterMune at ATS Skyfall Conference Call - Webcast
May 18, 2014
InterMune to Discuss Additional Pirfenidone Data in IPF Corporate Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -178.43% -313.88%
Operating margin -163.40% -293.61%
EBITD margin - -272.60%
Return on average assets -37.68% -53.45%
Return on average equity -87.46% -220.12%
Employees 353 -
CDP Score - -

Address

3280 Bayshore Blvd
BRISBANE, CA 94005
United States - Map
+1-415-4662200 (Phone)
+1-415-4662300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, the Company began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The cause of IPF is unknown. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics.

Officers and directors

Daniel G. Welch Chairman of the Board, President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John C. Hodgman Executive Vice President - Finance, Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Andrew Kenneth William Powell Esq. Executive Vice President, General Counsel, Corporate Secretary
Age: 56
Bio & Compensation  - Reuters
Giacomo Di Nepi Executive Vice President, Managing Director, Europe
Age: 60
Bio & Compensation  - Reuters
Paul D. Arata Executive Vice President - Human Resources and Administration
Age: 59
Bio & Compensation  - Reuters
Jonathan A. Leff M.D. Executive Vice President - Research and Development
Age: 56
Bio & Compensation  - Reuters
Sean P. Nolan Executive Vice President, Chief Business Officer
Age: 46
Bio & Compensation  - Reuters
Lars G. Ekman M.D., Ph.D. Lead Independent Director
Age: 64
Bio & Compensation  - Reuters
Jean-Jacques Bienaime Independent Director
Age: 60
Bio & Compensation  - Reuters
Louis C. Drapeau CPA Independent Director
Age: 70
Bio & Compensation  - Reuters